Selective elimination of alloreactive cells was carried out in the set-up of T-cell-mediated immunotherapy in an effort to gain the benefits of hematopoietic allogeneic transplantation while reducing the risk of GVHD. Low MW chemical compounds were screened for their effect on T-cell-mediated immune responses of murine-and human-derived lymphocytes. Selected compounds were further tested in secondary MLR assays in which sensitization to alloantigens was carried out in vitro, in the presence or absence of a given compound, followed by exposure to related and unrelated alloantigens or T-cell mitogenic stimulation. At a low concentration of o1 lM, a quinazoline derivative named AO#349 [2-(3,4,5-trimethoxyphenyl)-N-p-tolylquinazolin-4-amine], was able to induce 78-90% inhibition of a selective allogeneic response while retaining 492% immune reactivity to unrelated alloantigens and mitogenic stimuli in vitro. Following allogeneic sensitization in the presence of AO#349, elimination of alloreactivity to the priming alloantigens was also proved in a murine model of GVHD: 10 out of 15 sub-lethally irradiated mice inoculated with these sensitized cells were GVHD-free for 4200 days. AO#349 was efficient in induction of a selective elimination of alloreactivity and should be considered for clinical application in allogeneic cell-mediated immunotherapy.
Introduction
Immunosuppression is imperative in critical clinical situations of autoimmunity, allograft rejection and GVHD following organ and hematopoietic cell transplantation. However, currently available immunosuppressive modalities may cause all-encompassing suppression that is sometimes more harmful than helpful and therefore should be applied most carefully because of complications that may result from host's compromised immunoregulation and ineffective immunosurveillance. Similarly, pan-T-cell depletion of the hematopoietic allograft, which is generally efficient in preventing GVHD, has often been associated with increased risk of impaired engraftment, opportunistic infections and loss of graft vs malignancy effects. [1] [2] [3] [4] [5] As differential T-cell subsets have essential roles in the allograft implant as well as in immune reconstitution following hematopoietic cell transplantation, 6 achieving selective elimination of alloreactive T cells leaving resting lymphocytes intact, became an obvious clinical target. This strategy aims to gain the benefits of safer and more effective treatment of autoimmune disease as well as organ and allogeneic hematopoietic SCT while avoiding the detrimental circumstances of GVHD, infectious diseases and development of late malignant disorder. The concept of selective elimination of alloreactive T cells focusing on prevention of GVHD in the setting of allo-SCT has been tested by us and others previously, in various experimental models in vivo [7] [8] [9] as well as in an ex-vivo set-up using allogeneic priming in MLCs with or without extrication of the unwanted activated T cells. [10] [11] [12] [13] [14] The alloreactive T cells were sorted by means of (a) photosensitizing drugs, which can be preferentially incorporated and retained in activated T cells as opposed to resting T cells, 15, 16 (b) specific monoclonal antibodies directed against activation markers such as CD25, CD69, CD40L, CD134 and CD137 that are differentially expressed on activated T cells [17] [18] [19] [20] [21] [22] [23] [24] or (c) via activation-induced cell-mediated death by the CD95/ CD95L complex. 25, 26 Throughout our attempts to develop selective elimination of alloreactive T cells, which would allow for safe engraftment of allogeneic hematopoietic cells while controlling GVHD, we applied a pharmacological approach using synthetic low molecular chemical compounds that were screened for their ability to affect T-cell proliferation in response to mitogenic and allogeneic stimuli. The most effective compound that led to selective elimination of allogeneic cells in vitro was a quinazoline derivative, AO#349, which was further tested in vivo in a murine experimental model of GVHD.
Materials and methods

Mice
Female BALB/c H-2 d (BALB), C57BL/6 H-2 b (C57), SJL/j H-2s (SJL) and (BALB/c Â C57BL/6) F 1 H-2 d/b (F 1 ) mice aged 10-12 weeks, weighing 22-24 g, were used in this study. All mice were purchased from Harlan, Jerusalem, Israel, and maintained in the animal facility of the Hadassah University Hospital with sterilized food and water ad libitum, in full compliance with the regulations for the protection of animal rights.
Selection of optimal compounds for downregulation of T-cell reactivity Each new compound was added in serial dilutions into a T-cell proliferative assay in order to examine responsiveness of human lymphocytes to phytohemagglutinin and murine splenocytes to Con A. In each assay, a control of mitogenic stimulus without the 'tested compound' was included and referred as 100% response in 3 H-thymidine proliferation assay. Active compounds were considered positive when 50% of 3 H-thymidine uptake, determined by dose-response curve, was at a concentration of equal or o10 mM. Any compound that fulfilled this criterion was further examined in primary and secondary MLR as determined below in order to choose those that were selective inhibitors of alloreactive lymphocytes.
Chemical compounds
More than 1200 compounds with a variety of chemical structures were screened. Each compound was dissolved in DMSO to a final concentration of 50 mM and was subsequently diluted with culture medium (see below) to the required concentrations. A quinazoline derivative AO#349 2-(3,4,5-trimethoxyphenyl)-N-p-tolylquinazolin-4-amine [C 24 H 23 N 3 O 3 (MW ¼ 401)] that was identified as an active compound, was synthesized in larger quantities.
Murine and human cell sources Murine splenocytes were obtained from 2-to 4-month-old mice. Human PBMCs were obtained from 'buffy coats' collected from the peripheral blood of healthy human donors who had signed the appropriate informed consent forms of our hospital's blood bank. Mononuclear cells were separated on a Ficoll-Paque density gradient (Amersham Biosciences AB, Uppsala, Sweden).
Culture conditions
Culture medium consisted of RPMl 1640 medium supplemented with 100 U/mL penicillin, 100 mg/mL streptomycin, 2 mM L-glutamine, and serum as specified for each experiment. Unless otherwise stated, tissue culture media and reagents were purchased from Biological Industries, Beit Haemek, Israel. All cultures were incubated in a humidified incubator at 37 1C in 5% CO 2 .
Measurement of murine primary responses
Murine mitogenic responses. Naı¨ve C57 splenocytes (2-4 Â 10 5 ) were stimulated in vitro with 10 mg/mL Con A, or 2 ng/mL phorbol 12-myristate 13-acetate (PMA) plus 0.2 mM. Calcium ionophore (Ca 2 þ ) (Sigma Aldrich, Rehovot, Israel), in the absence or presence of 0.01-50 mM of the tested chemical compound. Stimulation was carried out in a flat 96-well plate (Nunc, Roskilde, Denmark) for 3 days and response was monitored by measuring radioactivity uptake as previously described. 27 One-way murine MLR. MLR and suppressive activity was carried out by culturing C57 splenocytes with irradiated BALB spleen cells with (0.01 to 50 mM) or without (control) the tested chemical compound, as previously described. 28 Cell-mediated lympholysis. Primary sensitization was carried out by MLC of 25 Â 10 6 C57 splenocytes incubated with 25 Â 10 6 irradiated (50 Gy) BALB splenocytes in a total volume of 20 mL culture medium supplemented with 10% heat-inactivated fetal bovine serum (GIBCO, Grand Island, NY, USA) and 50 mM 2-ME (Sigma Aldrich). Cells were incubated in 25cm 2 tissue culture flasks (Falcon Becton Dickinson Labware, Franklin Lakes, NJ, USA) at 37 1C in a humidified incubator for 5 days in the absence or presence of 0.5 mM AO#349. Measurement of cytotoxic activity against Con A blasts of BALB splenocytes was performed using 51 Cr-release assay as previously described. 29 AO#349 was present only in the MLC phase and was removed by washing the cells before the 4-h 51 Cr release assay.
Measurement of murine secondary responses C57 splenocytes were cultured with irradiated BALB splenocytes, with and without the tested chemical compound as described above for MLC. After 10 days, cells were collected, washed twice and resuspended in the same culture medium as that used for primary MLR assays to test alloreactivity to BALB splenocytes (related cells) and to SJL splenocytes (unrelated cells), or tested for their mitogenic response, as previously described. 10 Measurement of human primary responses Mitogenic response. Human PBMCs (l0 5 ) were cultured in flat-bottom 96 microwell plates (Nunc) with 3 mg/mL PHA, or PMA 2 ng/mL þ Ca ionophore 0.5 mM with (0.1 to 50 mM) or without the tested chemical compound. Response was monitored by measuring radioactivity as previously described. 10 One-way MLR assay. Responding cells derived from donor #1 (5 Â l0 4 ) were cultured in round-bottom 96-microwell plates with an equal number of irradiated (60 Gy) PBMC from donor #2 with (0.1 to 50 mM) or without the tested chemical compound. Cultures were incubated in a total volume of 0.2 mL culture medium supplemented with 15% heat-inactivated human AB þ serum for 6 days, as previously described. 10 Measurement of human secondary responses PBMC from donor #1 ( 10 7 ) were stimulated with irradiated (60 Gy) PBMC ( 10 7 ) from donor #2 with and without AO#349 (0.5 to 5 mM) in a total volume of 20 mL culture medium for 10 days, as previously detailed. 10 After 10 days, cells were washed and resuspended for alloreactivity and mitogenic assays, as already described.
10
Flow cytometry analysis Percentage of donor cells was determined in blood samples by fluorescence-activated cell sorting analysis using phycoerythrin anti-H-2 d and FITC anti-H-2 b antibodies (BD Biosciences, San Diego, CA, USA), as previously described. 27 Experimental design for GVHD induction In order to confirm deletion of alloreactive T cells by AO#349, we have chosen a most stringent GVHD induction system. Alloactivated C57 spleen cells sensitized in vitro against BALB stimulator cells, were injected into sub-lethally irradiated (BALB Â C57) F 1 mice in order to make sure that GVHD inducing cells will not be rejected and will induce lethal GVHD in the F 1 host mice.
Recipient F 1 mice were conditioned with non-lethal TBI of 6 Gy, using a 6MEV linear accelerator at a dose rate of 1.9 Gy/min. After 48 h, the sub-lethally irradiated recipients were inoculated i.v. with 30 Â 10 6 C57 splenocytes sensitized in vitro for 3 days with irradiated (50 Gy) BALB splenocytes at a cell ratio of 3/1 responding/stimulating cells in a final total cell concentration of 1.7 Â 10 6 /mL in the presence (0.5 mM) or without (control) AO#349. Another control group of mice was inoculated i.v. with 30 Â 10 6 naı¨ve C57 splenocytes. Samples of allogeneic-sensitized cells were taken for testing their ability to affect fresh allogeneic response in vitro as measured by MLR assay.
Mice were checked daily for the appearance of signs of GVHD, such as hunched posture, ruffled fur and diarrhea. Cachexia was assessed by body weight measured on a weekly basis. Survival was monitored and GVHD-related death determined on the basis of the aforementioned symptoms and post mortem examination.
Statistical analysis
Body weight was presented as mean±s.e. The KaplanMeier method was used to calculate the probability of survival as a function of time following cell inoculation. 30 The statistical significance of survival between pairs of Kaplan-Meier curves was evaluated by the log rank test. 31 A value of Po0.05 was considered statistically significant.
Results
Effect of AO#349 on proliferative and cytotoxic responses
The effect of AO#349 on proliferative mitogenic response was tested in vitro using murine splenocytes and humanderived PBMC. Proliferative response was calculated as a percentage of 3 H-TdR uptake relative to control cultures incubated without AO#349.
Mitogenic responses of C57 murine splenocytes stimulated with Con A or PMA þ Ca 2 þ ionophore, were efficiently inhibited in a dose-dependent manner in the presence of various concentrations of AO#349 (0.1-1.25 mM). Inhibition curves presented in Figure 1a display 50% mitogenic response at a concentration of 0.4-0.5 mM AO#349. A similar effect was achieved when human PBMC were stimulated with PHA or PMA þ Ca 2 þ ionophore in the presence of various concentrations of AO#349 (0.4-10 mM). Inhibition curves presented in Figure 1b display a 50% response to PHA and PMA þ Ca 2 þ ionophore stimuli at a concentration of 0.4 and 1.4 mM AO#349, respectively.
Allogeneic response of C57 splenocytes against irradiated BALB splenocytes in one-way MLR was totally inhibited (96%) in the presence of 0.5 mM AO#349 (Figure 2a) , as was the proliferative response of human PBMC to allogeneic stimulus in the presence of 2 mM AO#349 (Figure 2b) . Sensitization of C57 splenocytes with irradiated BALB splenocytes in the presence of AO#349 also prevented the generation of CTLs directed to BALB-derived cells, as measured by 51 Cr-release assay (Figure 3 ). In summary, AO#349 dose-dependent response curves show efficient inhibition of proliferative and cytotoxic responses to various mitogenic or allogeneic stimuli.
Recovery of murine alloreactivity and mitogenic responses following allosensitization in the presence of AO#349 C57 splenocytes primed against irradiated BALB cells, in the presence (0.5 mM, 1 mM) or absence (control) of AO#349, were assayed for the following functions: (1) the ability to react against the related priming alloantigens; (2) the ability to respond to unrelated alloantigens and (3) the ability to respond to a mitogenic stimulus, like Con A. Representative results presented in Figure 4a show that alloreactivity against the related priming alloantigens was inhibited (response o22%) when the drug was present in the priming phase of C57 anti-BALB reaction. Alloreactivity directed against unrelated SJL alloantigens and mitogenic response were fully recovered (498% response) by C57 anti-BALB cells primed in the presence of 0.5 or 1 mM AO#349. In summary, priming in the presence of the appropriate concentration of AO#349 inhibits secondary alloreactive responses directed to the priming alloantigens while sparing the response to unrelated alloantigens and mitogenic stimulus.
Recovery of alloreactivity and mitogenic responses of human PBMC following allogeneic sensitization in the presence of AO#349 Human PBMCs from donor #1 were primed for 10 days against irradiated PBMC from donor #2 in the presence (0.5 mM, 1 mM) or in the absence (control) of AO#349 and were assayed as already described. 10 The results presented in Figure 4b show that alloreactivity against the related priming alloantigens (donor #2) was significantly inhibited (o10% response) when AO#349 was present in the priming phase at a concentration of 1 mM. Alloreactivity directed against unrelated alloantigens (donor #3) was fully recovered (4107% response) when the priming phase was carried out in the presence of 0.5 or 1 mM AO#349. Mitogenic response of allogeneic cells primed in the presence of 0.5 or 1 mM was fully recovered (492%) but was inhibited (33% response) at a higher concentration of 5 mM AO#349 (data not shown). In summary, similarly to murine cells, priming of human PBMC in the presence of the appropriate AO#349 concentration (1 mM), inhibits secondary alloreactive responses directed to the priming alloantigens while sparing the responses to unrelated alloantigens and mitogenic stimulus.
Effect of AO#349 on immunosuppression induced in MLCs MLC of C57 anti-BALB splenocytes was carried out with (0.5 mM) or without AO#349 for 3 days, as described for GVHD induction in the Materials and methods section. To test the function of these 3-day MLC-sensitized cells, the cells were irradiated (1.5 Gy) in order to avoid their further proliferation, and added to fresh MLR in order to test their ability to affect fresh MLR of C57 anti-BALB cells. Results showed that cells derived from MLC carried out in the presence of AO#349, efficiently suppressed (12% response) allogeneic stimulation measured in MLR ( Table 1) .
Effect of AO#349 on GVHD induction in mice GVHD was induced in non-lethally irradiated F 1 mice inoculated with naive C57 splenocytes or C57 splenocytes sensitized in vitro with BALB cells (MLC) in the presence (0.5 mM) or absence of AO#349. There was no remarkable change in cell viability between the two cultures as determined by Trypan blue exclusion. All mice developed GVHD symptoms, but the most prominent symptoms manifested in mice inoculated with naı¨ve C57 cells. Body weight loss presented in Figure 5 is indicative of the severity of GVHD in these groups of mice. In all, 10 out of 15 mice Figure 6 ). The 10 remaining mice were alive and GVHD-free with a high percentage of C57 donor cells in blood samples tested and analyzed by FACS on day 220 following cell inoculation ( Table 2) .
Discussion
Screening of 41200 small chemical compounds in an attempt to achieve selective immunosuppression, resulted in the identification of one quinazoline derivative named AO#349. This compound was able to induce 78-90% inhibition of selective allogeneic response while retaining 492% immune reactivity to unrelated alloantigens and mitogenic stimulus in vitro at a low concentration of o1 mM. The same approach was used by us previously in the late 1980s, where an inhibitor of DNA polymerase a called aphidicolin, was introduced to the allosensitization phase of secondary MLR. 10 Although selective abrogation of alloreactivity was achieved in vitro, its potential application in vivo was associated with the risk of nonspecific inhibition of any proliferating cell on the one hand, and rapid inactivation of aphidicolin by liver microsomal oxidases on the other. In this study, we attempted to test chemical compounds with more restricted inhibition capability, which will allow application in low concentration as suitable for drug development. The chemical compound, which best fit this criterion was a quinazoline derivative, named by us AO#349 that was able to cause 450% inhibition of proliferative responses at low concentrations of 0.4-1 mM to various T-cell mitogenic stimuli, including T-cell receptor-independent pathway, as well as to allogeneic stimulus. This compound was also able to suppress induction of cytotoxic cells. The selective elimination of alloreactivity was genuine and related to AO#349: it could not be related to the solvent DMSO because it was achieved only with few out of total 1200 compounds tested and after being diluted by 41:50 000.
In order to evaluate the effect of each compound on CD4 and CD8-positive cells, we have analyzed the proliferative responses that are a function of CD4 and set a cytotoxic assay, which is a function primarily of CD8-positive T cells. Ninety percent of proliferation of murine splenocytes was inhibited and a complete inhibition of cytotoxicity was achieved at a concentration of 0.5 mM AO#349. Percentage of CD4 and CD3-positive cells was not affected by the presence of AO#349 as analyzed by flow cytometry (data not shown).
The presence of AO#349 during the sensitization phase induced a remarkable suppressive activity identified on addition of these cell-derived cultures to a fresh MLR assay. This in vitro-induced suppressor activity is probably responsible for the significantly reduced alloreactivity observed in vivo in our murine model of GVHD: no GVHD was observed over a follow-up period of 4200 days, while 85% hosts died of acute GVHD following inoculation of control-derived sensitized cells. It is worth noting that only the cells derived from MLC treated in the presence of AO#349 were able to suppress an allogeneic response in vitro and in vivo. It seems that the targeted absence of alloreactivity following allogeneic sensitization in vitro in the presence of AO#349 was not due to a general defective T-cell function because mitogenic response and alloreactivity to unrelated Ags were fully maintained. Efficient engraftment evidenced in the long-lived GVHDfree survivors (91% donor cells in peripheral blood samples taken 4200 days following cell inoculation) rules out the possibility that the absence of GVHD was due to donor cell rejection. Since alloreactivity was fully preserved against third party alloantigens, whereas it was unresponsive against related alloantigens, it seems reasonable that GVHD would not be preventable when sub-lethally irradiated recipients are challenged with unrelated alloreactive lymphocytes. However, this fact is not relevant for patients in need of allogeneic cell therapy. The AO#349 compound was able to induce selective elimination of alloreactivity in vitro, which could be utilized in a murine GVHD model in vivo. However, the compound could not be injected into mice because of its highly hydrophobic character and to the resulting high dilution from its DMSO solution, which is needed for direct inoculation in vivo (data not shown). Although easier and more efficient solutions are available for human clinical use, an improved water soluble derivative would allow further investigation in experimental models in vivo.
Among other small chemical compounds tested in the context of cell therapy and tolerance induction, there were tyrphostins, 32, 33 and our unpublished results and additional compounds that aimed to affect cell-mediated inflammatory responses. [34] [35] [36] Compounds such as bortezomib or PS-1145 were able to confer protection against acute GVHD in a follow-up time of 60-100 days. 37, 38 Another interesting immunosuppressive compound, which induced unresponsiveness to donor and recipient alloantigens but maintained a proliferative response to mitogenic stimulus was a synthetic analogue derivate of a traditional Chinese herb called (5R)-5-hydroxytriptolide (LLDT-8). This compound displayed immunosuppressive activities in murine-and human-derived lymphocytes in vitro 39, 40 as well as in transplantation and autoimmune models in vivo [39] [40] [41] but only over a limited follow-up time period of 60 days. 42 Another study that aimed to identify new pharmacological compounds capable of preventing acute GVHD, indicated the ability of a compound named NK026680 to affect APC, and especially DC function. This compound was effective in protecting 80% of the mice from acute GVHD over a follow-up period of 60 days, but only when applied as multiple daily injections up to a total high dose of 400 mg/kg, starting on the day of cell transplantation. Specific inhibition of allogeneic response was not reported in that study. 43 It is worth noting that another quinazoline derivate, named WHI-P131, was also able to prevent GVHD induction but its reactivity was only effective Selective elimination of alloreactivity S Morecki et al when given in combination with MTX for at least 85 days following transplantation. 44 As opposed to the short-term follow-up of the other chemical compounds, AO#349 compound proved to be efficient in inducing selective elimination of alloreactivity over a long-term follow-up without the need to expose the host to a foreign chemical compound. This means that in accordance with our observations to date, AO#349 can be utilized for the prevention of GVHD, but its application for in vivo treatment of already existing GVHD, as well as its possible application for autoimmune and other inflammatory diseases requires future investigation.
The immunosuppressive mechanism of AO#349 was recently investigated. 45 Both AO#349 and some of its analogues, to a lesser extent, inhibited proliferation of Jurkat cells in addition to human peripheral T cells, with IC 50 of o1 mM. It was discovered that the inhibition was mediated by G2 cell cycle arrest without inhibition of IL-2 secretion. It seemed that a reduction of SLP-76 phosphorylation, as visualized by western blot, have a major part in the immunosuppressive effects of AO#349. However, unique signaling molecules, probably unique kinases, which may act selectively on lymphocytes rather than on other cell types might also have a relevant role. It was therefore suggested that the predominant effect was mediated by G2 cycle arrest not excluding additional reactivity of other molecules or kinases, which might interfere with cell proliferation following stimulations of lymphocytes.
Owing to the partially shared biology of GVHD and antitumor activity, prevention and/or control of GVHD by immunosuppressive methods of any kind, including selective elimination of donor anti-host alloreactivity, must ensure that the eradication of malignant cells is retained. Experimental models in which selective allodepletion could be separable from anti-tumor effect, have been documented by others and by us 15, 19, 23, 24, 26, 46 and could be explained on the basis of overexpression of tumor-associated or tumor-specific Ags and/or to development of clones with specific reactivity against such Ags, independently from Ags expressed by normal host tissues. In line with these observations, AO#349 should be tested in murine models of hematopoietic transplantation aiming to induce immune reactivity against hematological and solid malignancies. Considering the fact that allo-SCT is the treatment of choice for an increasing number of life-threatening non-malignant diseases, the feasibility to engraft fully mismatched lymphocytes while avoiding GVHD per se seems to be a rather important challenge. Furthermore, the feasibility to induce selective unresponsiveness to alloantigens may open new horizons for the prevention of allograft rejection, applicable for prevention of rejection of haploidentical stem cells for a large number of patients in need of SCT for treatment of malignant and non-malignant disorders, including BM deficiency disorders and genetic diseases correctible by transplantation of normal stem cells. Similarly, such an approach might be applicable for induction of unresponsiveness to mismatched organ allografts that can be induced by co-injection of donor stem cells, thus avoiding the need for life-long immunosuppressive treatment, which is accompanied by drug-related complications and increased incidence of secondary malignancy.
The efficient elimination of selected alloreactive cells as proved in vitro and in vivo, while sparing other T-cellmediated immune reactivities directed to unrelated allogeneic and mitogenic stimuli, justifies further investigation of the compound AO#349 and its application for clinical use in allo-SCT and T-cell-mediated immunotherapy aimed to downregulate uncontrolled cell proliferation.
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